Caratterizzazione del profilo di metilazione di campioni conservati presso il Centro Risorse Biologiche (CRB) dell’ Istituto Ortopedico Rizzoli (IOR)

Title

Code

DNAmetCRB

Type

In Vitro

Start Year

2025

Status

In Corso

Principal Investigator

051-6366519, 051-6366681

luca.sangiorgi@ior.it

Sangiorgi Luca, MD

Director

Rare skeletal disorders

Operational unit that carry out the study

complex unit

Malattie rare scheletriche

Director

Sangiorgi Luca, MD

Go to the details >>

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio prot. DNAmetCRB

Tuesday 8 April 2025, 11:25

PG0004636_2025_Stampa_unica.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

IRCCS

ISTITUTO ORTOPEDICO RIZZOLI

Caratterizzazione del profilo di metilazione di campioni conservati presso il Centro Risorse Biologiche (CRB) dell’ Istituto Ortopedico Rizzoli (IOR)

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Sito Web Istituto Ortopedico Rizzoli

Caratterizzazione del profilo di metilazione di campioni conservati presso il Centro Risorse Biologiche (CRB) dell’ Istituto Ortopedico Rizzoli (IOR)

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in